Tonnerre, Pierre http://orcid.org/0000-0002-1719-9736
Wolski, David
Subudhi, Sonu http://orcid.org/0000-0002-5937-1880
Aljabban, Jihad
Hoogeveen, Ruben C.
Damasio, Marcos
Drescher, Hannah K.
Bartsch, Lea M.
Tully, Damien C. http://orcid.org/0000-0002-7620-9340
Sen, Debattama R. http://orcid.org/0000-0002-0947-8284
Bean, David J. http://orcid.org/0000-0001-7497-8026
Brown, Joelle http://orcid.org/0000-0001-6933-7056
Torres-Cornejo, Almudena
Robidoux, Maxwell
Kvistad, Daniel
Alatrakchi, Nadia
Cui, Ang http://orcid.org/0000-0002-1087-8568
Lieb, David http://orcid.org/0000-0001-7459-4719
Cheney, James A.
Gustafson, Jenna
Lewis-Ximenez, Lia L.
Massenet-Regad, Lucile http://orcid.org/0000-0003-1629-8983
Eisenhaure, Thomas http://orcid.org/0000-0003-3999-3540
Aneja, Jasneet
Haining, W. Nicholas http://orcid.org/0000-0001-7871-3762
Chung, Raymond T.
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Allen, Todd M. http://orcid.org/0000-0002-6609-1318
Kim, Arthur Y.
Lauer, Georg M. http://orcid.org/0000-0002-9792-4271
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U19 AI086230, U19 AI086230, U19 AI086230, U19 AI086230, U19 AI086230, U19 AI086230, U01 AI131314, R01 DA046277, U01 AI131314)
Article History
Received: 18 May 2020
Accepted: 22 June 2021
First Online: 26 July 2021
Competing interests
: AbbVie sponsored the clinical trial (ExternalRef removed) and provided input in the trial design and clinical and biological sample collection schedule. W.N.H. is an employee of Merck and Company and holds equity in Tango Therapeutics and Arsenal Biosciences. All other authors declare no competing interests.